Credit: Canva
Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, and go beyond their usual boundaries to invade adjoining parts of the body. According to the World Health Organization (WHO), it is the second most common cause of death globally, accounting for millions of deaths every year. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. However, these are not necessarily the deadliest forms of cancer.
What makes cancer the deadliest depends upon how many people have it and what percentage of those people actually survive. Cancer researchers determine this on the basis of five-year relative survival. This is the percentage of people who are expected to survive the effects of a given cancer, excluding their risk of other possible causes of death, for five years past a diagnosis. It is also important to note that what makes cancer really deadly is that practically no cure for it. A cure for cancer would imply that there are no cancerous cells remaining in the body.
Here are the 5 deadliest cancers in the U.S., according to SEER five-year relative survival data for cases diagnosed between 2014 and 2020.
1. Pancreatic cancer occurs when cells in your pancreas, a gland in your abdomen that aids digestion, mutate and multiply out of control, forming a tumour. Major risk factors include smoking, obesity, diabetes, chronic pancreatitis, certain genetic mutations and environmental chemical exposure.
2. Esophageal cancer develops in the oesophagus, which is the tube that connects your throat to your stomach.
3. Liver cancer and intrahepatic bile duct cancer originate in the liver or bile ducts, often linked to hepatitis infections, heavy alcohol use, obesity, and aflatoxin exposure.
4. Lung and bronchus cancer primarily caused by smoking, secondhand smoke, and environmental pollutants, affects the lungs and airways, making it the leading cause of cancer death in the US.
5. Acute myeloid leukaemia (AML) is an aggressive blood and bone marrow cancer that progresses rapidly, often linked to genetic mutations, radiation exposure, and certain chemicals.
ALSO READ: Why Are Lifestyle Factors Making Millennials Vulnerable To Cancer?
Credit: Health Ministry/X
Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.
Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.
The President noted that malaria remains a serious public health challenge in several countries, including India.
Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.
"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.
India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.
As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.
Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.
She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.
Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.
The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.
She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.
Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.
Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.
Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.
The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.
"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.
The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.
Credit: AI-generated image
Faulty radon detectors have sparked concern after Health Canada issued a warning about how inaccurate readings on devices sold online could mislead consumers. The advisory issued recently says that faulty detectors could underestimate radon levels, giving consumers a false sense of security about their exposure to the cancer-causing gas.
It talks about electronic radon monitors and home-testing kits that have previously recalled after it was found that they gave inaccurate readings.
Among the products Health Canada has previously warned against are the InkBird WiFi Radon Detector (model RD-2), Life Basis radon detectors, Hanchen Home Radon Detector and Spolehli radon detectors. The agency has also issued warnings about other radon-monitoring devices sold online.
Inaccurate readings can be problematic in both ways. A detector may report radon levels lower than they actually are, leaving people exposed to dangerous concentrations without their knowledge. On the other hand, it may report higher levels than those present, causing unnecessary panic.
Health Canada recommends that consumers choose electronic radon monitors that have passed performance testing by the Canadian National Radon Proficiency Program (C-NRPP).
Radon is a naturally occurring radioactive gas released when uranium in soil and rocks breaks down. It is invisible, odourless and tasteless, making it impossible to detect without specialised equipment.
The gas can enter buildings through cracks in foundations, gaps around pipes, floor drains and other openings.
While radon disperses quickly in outdoor air, it can accumulate to high concentrations indoors, especially basements and poorly-ventilated areas.
Long-term exposure to highradon levels increases the risk of lung cancer. According to Health Canada, radon is the second-leading cause of lung cancer in Canada after smoking and the leading cause among people who have never smoked.
The risk depends on both the concentration of radon in the air and how long a person is exposed. People who smoke and are exposed to radon face an even greater risk of lung cancer.
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Radon decays into radioactive particles that can be inhaled through breathing. These particles release radiation that can damage the DNA of lung cells. Long-time exposure can lead to genetic changes that contribute to cancer.
The International Agency for Research on Cancer (IARC) classifies radon as a Group 1 carcinogen, meaning there is sufficient evidence that it causes cancer in humans.
Health Canada recommends long-term testing to determine the average radon concentration in your home. A test lasting at least three months provides a more reliable assessment than short-term measurements because radon levels can fluctuate with weather, ventilation and seasonal changes.
Consumers should:
Health Canada's guideline for indoor radon is 200 becquerels per cubic metre (Bq/m³). If the average level is above this threshold, homeowners should take action within one year and consult a certified professional.
Credit: AI-generated image
Clinical trials investigating experimental treatments for rare, aggressive childhood brain cancers have been disrupted after the closure of a US research consortium that was in operation for 27 years.
The shutdown of the Pediatric Brain Tumor Consortium (PBTC), after the National Cancer Institute (NCI) declined to renew its funding, has caused significant delays and rendered desperate families searching for alternative treatment options.
The consortium was composed of 16 leading children's hospitals and academic medical centres across the US, aiming to investigate new treatments for aggressive brain tumours, including diffuse intrinsic pontine glioma (DIPG) and ependymoma.
The NCI informed consortium leaders about the decision in August 2025, ending its approximately $4 million annual grant. Eight ongoing clinical trials were subsequently halted, according to The New York Times.
The consortium formally dissolved in September 2026. Researchers say the disruption has affected not only ongoing studies but also the infrastructure and resources needed to develop new treatments for childhood brain cancers.
Also read: Losing Balance While Walking? Doctors Explain When It Could Be A Neurological Warning Sign
DIPG is a rare, aggressive brain tumour that usually affects children between four and 10 years of age. It develops in the pons, a part of the brainstem which is responsible for essential functions like breathing, heart rate, coordination and balance.
Since the tumour grows within critical brain tissue and spreads through the brainstem, it cannot be removed through surgery. Clinicians describe it “like sand in grass”.
Radiation therapy is commonly used to fight the tumour but its benefits are temporary. There is currently no established treatment. The average survival after diagnosis is approximately nine to 12 months.
With limited treatment options, clinical trials investigating experimental therapies are a need of the hour for children suffering from DIPG.
Also read: AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida
The closure disrupted several studies exploring experimental treatments for childhood brain tumours.
One of the affected studies, PBTC-059, was a Phase 1 trial investigating CAR-T cell therapy in children with ependymoma. CAR-T therapy entails modifying a patient's immune cells to identify and attack cancer cells.
Another study, PBTC-N14, was discontinued too. Researchers at Memorial Sloan Kettering Cancer Center were investigating whether cerebrospinal fluid samples could provide genetic information similar to that obtained through an invasive brain biopsy, reducing the need for surgery in some children.
Researchers were also exploring other experimental options for DIPG, including cancer vaccines and devices that can deliver electrical stimulation to the brain.
According to the NCI's updated information, some paused trials are expected to reopen to patient enrolment in late 2026 or early 2027. But the interruption has created a significant gap and delay for families who were previously able to access these trials.
The consequences of the consortium's closure extend well beyond clinical trial enrolment and patient welfare. At St. Jude Children's Research Hospital, 27 years of research data involving more than 2,000 children with rare brain tumours had to be archived.
Hundreds of biological samples, including tumour tissue, blood and spinal fluid collected from patients, also had to be returned to hospitals or destroyed if they could not be retained.
Researchers have raised concerns that losing the consortium's dedicated infrastructure and centralised data-access system could make it harder for scientists to resume these studies and build on previous findings.
Ira Dunkel, a paediatric oncologist at Memorial Sloan Kettering Cancer Center and former chair of the consortium, described the closure as “catastrophic” and one of the worst professional moments of his career.
The NCI said the decision was taken to improve efficiency by moving the consortium's data into the larger Pediatric Early Phase Clinical Trials Network. The institute also said enrolment in some consortium studies had slowed.
But researchers argued that the smaller patient populations and the highly targeted nature of experimental treatments make specialised research areas particularly important.
After the decision, NCI announced that approximately $4 million would be allocated to the larger network to strengthen paediatric brain tumour research and accelerate Phase 1 clinical trials.
The $4 million grant also seemed insufficient compared to the $732 million that the NIH spends annually on childhood cancer. But according to Dunkel, it was “hugely important”.
But researchers and patient support groups have questioned whether the larger network can immediately and effectively replace the consortium's specialised expertise, proven collaborations and research infrastructure.
A bipartisan group of lawmakers from New York called wrote to Health and Human Services Secretary Robert F. Kennedy Jr., urging to reverse the decision. “We cannot afford to take this step backward,” the group said.
Families dealing with aggressive childhood brain cancers are helpless in the light of consortium closure. With some children having less than a year after diagnosis, such setbacks mean losing access to potentially life-saving or extending experimental treatment opportunities that may not become available again in time.
© $2026 Times Horizon Private Limited